Nc Sickle Cell Syndrome Program
NC Sickle Cell Syndrome Program shared Love Quotes and Sayings's photo. December 10, 2012 Love Quotes and Sayings is with Ninz T. Mandario and 43 others. Sickle Cell Disease in North Carolina What is Sickle Cell Disease. • Pneumonia/Acute Chest Syndrome (ACS). For more information on the NC Sickle Cell Program. NC Sickle Cell Syndrome Program. NC Sickle Cell Syndrome Program - Helps families and patients to deal with the reality of the disease.
Mainconcept mpeg encoder 1.4.2 torrent. Dates: October 6-7, 2017 Location: Duke University School of Nursing, Durham, NC Description The 6th annual Sickle Cell Disease Conference encompasses a two-day event to discuss the effects and treatment of SCD. We have an exciting, brand new conference planned this year with three nationally recognized SCD experts as speakers. The conference will include both lecture and Q&A panels to directly answer participants’ questions.
Why Should You Attend? Sickle cell disease affects approximately 100,000 Americans. This conference, designed for both health care providers and patients and families dealing with SCD, will highlight many of the complications as well as treatments for this disease. The conference goals include:. To provide knowledge about common medical and psychosocial complications of SCD in adults and children.
To understand patient-centered approaches to the care of individuals and families living with SCD. To become informed on the latest SCD research. Who Should Attend? Day 1 will focus on education for health care providers (including nurses, social workers, therapists, pharmacists, physician assistants, physicians and others) and educators, community members, and medical and nursing students; Day 2 will focus on education for individuals and families living with SCD. We encourage participation from health care providers and individuals with SCD on both days, but childcare will be provided only on Saturday. Agenda Friday, October 6, 2017 Time Room 1014 7:30am - 8:30am Registration & Survey 8:30am - 8:45am Welcome and Opening Remarks 8:45am - 9:30am Sickle 101 - Pathophysiology and Complications - Ifeyinwa (Ify) Osunkwo, MD, MPH 9:30am - 10:15am Ground Breaking Research in SCD: DOVE Study, SUSTAIN Study, RESET Study - Julie Kanter, MD - Nirmish Shah, MD - Marilyn Telen, MD 10:15am - 10:30am BREAK 10:30am - 11:30am What's the latest research at your SCD Center?
- Ifeyinwa (Ify) Osunkwo, MD, MPH - Nirmish Shah, MD - David Wichlan, BA, MS 11:30am - 12:15pm What's the latest in gene therapy and transplant? - Julie Kanter, MD 12:15pm - 1:15pm LUNCH and POSTERS 1:15pm - 2:00pm What do you know about fatigue and sleep in SCD?
- Cecelia Valrie, PhD 2:00pm - 3:00pm Panel Discussion: Patient Resources and Partnerships - Sandra Boyd, MA - Debbie Murray, RN - Monica Summers 3:00 pm - 3:15pm BREAK 3:15 pm - 4:00pm Empowering Providers and Educators - Tiffany Bell, MSW 4:00 pm - 4:10pm Closing Remarks Saturday, October 7, 2017 Time Room 1014 Room 1026 8:30am - 9:30am Registration & Survey 9:30am - 10:15am Promoting Lifelong Management - Shirley Milller, MA 10:15am - 11:00am Optimizing your Health and Quality of Life - John J. Strouse, MD, PhD 11:00am - 11:15am BREAK 11:15am - 12:00pm Research in the News - Jennifer A. Rothman, MD - Nirmish Shah, MD 12:00pm - 1:00pm Panel Discussion: Community - Patient Resources and Partnerships - Tiffany A.
Bell, MSW - Sandra C. Boyd, MA - Deborah A. Murray, RN, CMAC, CHC, CPN, CNM 1:00pm - 1:45pm LUNCH and POSTERS 1:45pm - 2:30pm What's the Latest in Adult and Pediatric Transplant - Lakshmanan Krishnamurti, MD 2:30pm - 3:15pm Panel Discussion: Let's Talk Transition - Ifeyinwa (Ify) Osunkwo, MD, MPH - Nirmish Shah, MD Communicating with your Healthcare Providers - Cheryl Brewer, PhD, MSN, RN Patients 3:15pm - 3:45pm Closing Remarks Question & Answer Speakers David Wichlan, BA, MS David Wichlan has more than 15 years of clinical research experience in Bone Marrow Transplantation, Hemophilia and Sickle Cell Disease. He is currently the clinical research coordinator for the University of North Carolina Comprehensive Sickle Cell Center. Jennifer Rothman, MD.
Dr. Jennifer Rothman is the director of the Duke Pediatric Comprehensive Sickle Cell Program. Her clinical and research interests include neurologic and neurocognitive outcomes of sickle cell disease, novel uses of hydroxurea for the treatment of sickle cell disease, and participation in studies to evaluate new and novel methods of managing the complications of sickle cell disease. Strouse, MD, PhD. Dr. Strouse completed a combined residency in Pediatrics and Internal Medicine at the University of Rochester and a combined fellowship in Hematology (National Institutes of health) and Pediatric Hematology/Oncology (Johns Hopkins University School of Medicine and National Institutes of Health).
He was an assistant professor of Pediatrics and Medicine at Johns Hopkins University before moving to Duke University as an associate professor of Medicine and Pediatrics and director of the Adult Sickle Cell Program. His research has focused on the epidemiology, risk factors, and prevention of the pulmonary and central nervous system complications of sickle cell disease and includes retrospective and prospective cohort studies and clinical trials. He received his PhD in clinical investigation from the Johns Hopkins Bloomberg School of Public Health for a series of studies to identify predictors of cognitive function in children with sickle cell disease. This work has expanded to the evaluation of the interaction between environment and disease in both children and adults with sickle cell disease.
Other research interests include the application of large clinical, research, and administrative databases to the study of rare hematological diseases and interventions to improve quality of and access to care for sickle cell disease. Strouse has expertise in the diagnosis and treatment of children and adults with non-malignant blood disorders with special interest in sickle cell disease and other hemoglobinopathies Julie Kanter, MD. Dr. Julie Kanter is a hematologist focusing on the care of children and adults with sickle cell disease. She is an associate professor of Pediatrics at the Medical University of South Carolina and runs the first all-ages, Lifespan Comprehensive Sickle Cell Center. Kanter works closely with national partners including the Sickle Cell Disease Association of American and American Society of Hematology to improve the lives of individuals living with sickle cell disease. In 2016, Kanter and her team was awarded one of eight of the NHLBI sickle cell disease implementation grants to form a sickle cell implementation center.
She is also very interested in expanding access to care for patients with sickle cell disease through the statewide program (SC)2. Kanter has authored and co-authored more than 50 articles, book chapters, and abstracts and hopes to train upcoming physicians and providers in sickle cell disease to expand the workforce for treating affected individuals. Shirley Miller, MA. Shirley Miller has over 20 years of program management and patient advocacy experience in sickle cell disease.
Miller currently serves as the manager of Community Programs for the adult sickle cell disease comprehensive program at Carolinas HealthCare System in Charlotte, NC. She serves as an advisor on the Food and Drug Administration center for drug evaluation and as an advocate on the National Heart Lung and Blood Sickle Cell Disease Advisory Committee. Miller is the author of the book entitled “The Stranger Within Me” and a volunteer coordinator for the Sickle Cell Adult Provider Network (SCAPN). She holds a bachelors’ degree in Business Administration and a masters’ degree in Psychology. Murray, RN, CMAC, CHC, CPN, CNM Debbie Murray works with Community Care of North Carolina.
She is a registered nurse who is certified in care management administration, pediatric nursing and in health coaching. Starting out as a high school teacher, Murray believes that education is a key component of helping patients maintain and manage their health. Nirmish Shah, MD. As director of Duke’s sickle cell transition program, Shah's practice and research focuses on treating children and adults with sickle cell disease. When working with children, he focuses on teaching them about their condition and how to transition successfully to living with the disease as an adult. For all patients, Shah focuses on providing the medical, social and psychological support they need to remain healthy.
His research aims to increase engagement of sickle cell patients with their own care using mobile technology. Through the use of applications, he's hoping to help patients, specifically children, better manage their symptoms and medications. Lakshmanan Krishnamurti, MD Ifeyinwa (Ify) Osunkwo, MD, MPH.
Nc Sickle Cell Syndrome Program Service Codes
Dr Ifeyinwa Osunkwo is a lifespan hematologist and SCD expert with over 25 years of experience in the management of adults and children with SCD. She is the medical director of the sickle cell disease enterprise for Carolinas Healthcare System (CHS) and the Levine Cancer Institute in Charlotte NC. Her mission is to improve the quality of life for all persons living with sickle cell disease in the Carolinas and over the past three years she has established a Comprehensive Sickle Cell Center of Excellence at CHS serving 1300 adults with the help of a multi-disciplinary team using the chronic disease management model. This model links all patients into a medical neighborhood based on disease severity and available resources and infrastructure. Dr Osunkwo believes strongly that “you have to manage the patient as a whole person and not just dealing with emergencies or pain.” She supports the Carolinas Healthcare Systems mission “To improve health, elevate hope and advance healing for all” (living with SCD). Sandra Boyd, MA Sandra Boyd serves as program supervisor for the North Carolina Sickle Cell Syndrome Program in Raleigh, NC. She has worked in public health for 32 years combined with the State of North Carolina and Lee County Public Health in Sanford, NC.
Her experiences include working with women’s and children’s health Issues, including: HIV/AIDS and other sexually transmitted diseases, community health education and promotion programs, sickle cell disease and she worked for 10 years as a mental health counselor. She received her Bachelor of Science in Community Health Education and Masters of Arts in Counseling Education from North Carolina Central University in Durham, NC. Boyd is a native Sanford and spends her free time organizing her photo albums, reading and spending time with the family. She is married to David Boyd, Sr. And they have three children, David, Grant and Gabrielle.
Monica Summers Monica Summers has been employed with Piedmont Health Services and Sickle Cell Agency (PHSSCA) for 18 years and is program director for the Sickle Cell Division, Camp Director, and Emergency Food Pantry Coordinator. In 2003, Summers became a certified sickle cell educator/counselor through The University of South Alabama Comprehensive Sickle Cell Center.
She received her Master’s Degree in Public Health from Liberty University in 2014. Educating others about SCD is a personal mission for her. Summers along with her husband, Channing Sr., whom has been married for 15 years, continues to work full time and care for their two children, CJ (14) and Jayla (10), who have SCD. Summers knows from personal experience the needs that many parents of children with SCD face; because these are the same needs that she faces. Marilyn Telen, MD. Dr.
Marilyn Telen is known internationally for her research on red cell membrane protein biochemistry and genetics, and for discovering the roles that blood group antigen proteins play in normal cell biology and the pathophysiology of sickle cell disease. Her current laboratory-based work focuses on the role of red cell adhesion molecules in sickle cell disease, as well as on the conduct of genetic and clinical translational research in sickle cell disease and transfusion medicine. Telen has recently worked to help develop new drugs for sickle cell disease; she was coordinating investigator for the Phase 2 study of rivipansel and is currently on the steering committee for the ongoing phase 3 study of that drug. Tiffany Bell, MSW Tiffany Bell completed her MSW in 2015 from North Carolina Central University and her BSW in 2004 from the University of North Carolina at Charlotte. Prior to working in the Hematology Department Bell worked in the Infectious Disease Department at Duke University Medical Center as HIV/AIDS Housing case manager.
In her free time, she enjoys cooking, traveling and spending time with family and friends. Cecelia Valrie, PhD Dr. Cecelia Valrie, associate professor of Psychology at Virginia Commonwealth University, is a developmental-health psychologist who focuses on improving the health and well-being of youth and young adults with sickle cell disease (SCD).
Specific areas of focus include investigating the relations between acute and chronic pain, sleep, fatigue, and quality of life in youth with SCD, and developing and implementing behavioral interventions to improve symptom management and outcomes in youth and young adults with SCD, with a focus on eHealth and mHealth interventions. Cheryl Brewer, PhD, MSN, RN.Conflicts of Interest: Members of the commitee and speakers have no conflicts of interst, except for the following: Nirmish Shah, MD: Novartis, self-developed slide deck on transition in SCD; Julie Kanter, MD: Serves as a stie PI for Bluebird BIO gene therapy study; John J. Strouse, MD: Honorarium - EBSCO for Dynamed SCD educational module; Shirley Miller, MA: Serves as patient advisor for Pfizer, Sancilio, FDA, NHLBI; Ify Osunkwo, MD, MPH: Novartis Pharmaceuticals, JADE, Advisory Board Novartis; Jennifer Rothman, MD: Salary - local principal investigator for Pfizer RESET Study, Chair of Operations Committee RESET study and Pfizer; Marilyn Telen, MD: Paid by Pfizer to serve on the Steering Commitee of the RESET trial.
HOW DOES STEM CELL THERAPY PLUS WORK? Stem Cell Therapy Plus uses the same principle as traditional stem cell therapy but with much less cost, less risk, yet similar or more effectiveness. Stem Cell Therapy Plus starts with the selection of specific organ cells from an animal fetus (unborn young) bred specifically for this purpose. Many years of experience have shown that sheep are the best donor animals because they are vital, hardy animals with the best immune systems and natural disease resistance. Sheep proteins are particularly compatible with the human body and trigger no immune reactions. In Stem Cell Therapy Plus, these vigorous young stem cells, with their vital life force still active, are ingested into a human host via high-tech softgel bio-active Stem Cell PE Capsules. Since stem cells have NO antigens, they are NOT recognized as foreign by the host body.
According to Dr. Niehans’ proven theory, they circulate from the site of ingestion (small intestines) until they recognize and congregate at the human counterpart of the organ from which they were taken – pancreas cells go to the pancreas, brain cells go to the brain, nerves cells go to the nerves, cartilage cells go to the cartilages, heart cells go to the heart, etc. These young stem cells, which are functionally organ specific but not species specific, imprint their vigor upon old, tired, and degenerating cells, stimulating them to function with renewed efficiency.
Sickle Cell Trait
The organ itself then retains its vigor and vitality. In addition to effectively stimulate the cells of specific organ systems, these new and energetic stem cells act quickly to revitalize the body immune system & defense mechanisms. When damage occurs to the cells that make up the various tissues and organs involved in the immune systems (either through the ageing process or from environmental poisons), the body becomes defenseless against both external invasion and internal degeneration. Damage to specific organs and immune system may be reversed through revitalization & regeneration with Stem Cell Therapy Plus. Anecdotal evidence shows that through the usage of Stem Cell Therapy Plus, improvements can be seen in the case of some degenerative diseases as aforementioned.